Survival of Patients with Malignant Pleural Effusion: A Single Center Study
(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)

Name: Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Author: Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif

İsim	Survival of Patients with Malignant Pleural Effusion: A Single Center Study
İsim Orijinal	Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Yazar	Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Basım Tarihi:	1401
Basım Yeri	Shiraz University of Medical Sciences - Shiraz University of Medical Sciences
Konu	malignant, pleural effusion, survival
Tür	Süreli Yayın
Dil	Arapça
Dijital	Evet
Yazma	Hayır
Kütüphane:	Girona Üniversitesi
Demirbaş Numarası	EISSN: 2322-4339, DOI: 10.30476/smsj.2023.95854.1354
Kayıt Numarası	cdi_doaj_primary_oai_doaj_org_article_ea74ee8bfe754a35aed51313fc821cc2
Lokasyon	Available Online
Tarih	1401
Örnek Metin	Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.

Kaynağa git Girona Üniversitesi Universitat de Girona

Diğer Nüshalar

Girona Üniversitesi

Kaynağa git

Survival of Patients with Malignant Pleural Effusion: A Single Center Study

(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)

Yazar Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif

Basım Tarihi 1401

Basım Yeri Shiraz University of Medical Sciences - Shiraz University of Medical Sciences

Konu malignant, pleural effusion, survival

Tür Süreli Yayın

Dil Arapça

Dijital Evet

Yazma Hayır

Kütüphane Girona Üniversitesi

Demirbaş Numarası EISSN: 2322-4339, DOI: 10.30476/smsj.2023.95854.1354

Kayıt Numarası cdi_doaj_primary_oai_doaj_org_article_ea74ee8bfe754a35aed51313fc821cc2

Lokasyon Available Online

Tarih 1401

Örnek Metin Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.

Survival of Patients with Malignant Pleural Effusion: A Single Center Study
(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)

Diğer Nüshalar